A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response
Scott Berry(Queen's University), Christopher W. Woods(Duke University), David L. Hoover(Agricultural Research Service), James B. Russell(University of Sierra Leone), Nathan M. Thielman(Duke University), Elizabeth Petzold(Duke Medical Center), Coleen K. Cunningham(Duke Medical Center), G. Ralph Corey(Duke Medical Center), Peter Dull(Gates Foundation), J. McLeod Griffiss(Clinical Research Management), Micah T. McClain(Duke University)
Cited by 68
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818